Proliferation_and_cytolytic_function_of_anti-CD3_+_interleukin-2_stimulated_peripheral_blood_mononuclear_cells_following_bone_marrow_transplantation._We_evaluated_the_proliferation,_cytolytic_function,_and_phenotypic_characteristics_of_anti-CD3_plus_interleukin-2_(IL-2)_stimulated_peripheral_blood_mononuclear_cells_(PBMCs)_from_44_patients_with_leukemia_or_non-Hodgkin's_lymphoma_(NHL)_treated_with_multiagent_chemotherapy_or_following_bone_marrow_transplantation_(BMT)._BMT_patients_had_decreased_cell_growth_with_only_a_1.35_+/-_0.25_(autologous_BMT_for_acute_lymphoblastic_leukemia_ALL),_1.24_+/-_0.25_(autologous_BMT_for_NHL),_and_0.8_+/-_0.1_(allogeneic_BMT_for_leukemia)_mean_fold_increase_by_day_5_of_culture_compared_with_controls_(4.0_+/-_0.4),_P_less_than_.001._Anti-CD3_+_IL-2_activated_cells_from_patients_with_ALL_and_NHL_who_had_received_autologous_BMT_and_cells_from_patients_with_leukemia_who_underwent_allogeneic_BMT_were_more_effective_in_lysing_the_natural_killer_(NK)_sensitive_target,_K562,_and_the_NK-resistant_target,_Daudi,_compared_with_controls._In_contrast,_cytolysis_of_K562_and_Daudi_by_cultured_PBMCs_from_patients_with_ALL_and_NHL_receiving_multi-agent_chemotherapy_was_similar_to_that_of_controls._Cultures_from_BMT_recipients_had_a_significant_increase_in_CD16+_(autologous_ALL_5.7_+/-_1.5%,_P_less_than_.01;_autologous_NHL_12.4_+/-_3.5%,_P_less_than_.001;_allogeneic_14.3_+/-_2.9%,_P_less_than_.001)_and_CD56+_cells_(autologous_ALL_27.6_+/-_12.0%,_P_less_than_.01;_autologous_NHL_39.3_+/-_9.5%,_P_less_than_.001;_allogeneic_42.7_+/-_7.4%,_P_less_than_.001)_compared_with_controls_(CD16+_2.5_+/-_0.4%;_CD56+_6.9_+/-_0.9%)._Stimulation_of_PBMCs_with_anti-CD3_+_IL-2_is_effective_in_generating_cells_with_high_cytolytic_function_post-BMT.